Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  Angiogenex Inc    AGGX

ANGIOGENEX INC (AGGX)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCompany 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Otc Bulletin Board - Othe…
05/18/2018 05/23/2018 05/25/2018 06/04/2018 06/22/2018 Date
0.22(c) 0.22(c) 0.22(c) 0.3(c) 0.31(c) Last
276 1 000 227 7 500 85 204 Volume
+4.76% 0.00% 0.00% +36.36% +3.33% Change
More quotes
Company
AngioGenex, Inc. operates as a biopharmaceutical company, which engages in developing and commercializing novel platform of anti-proliferative drugs for the treatment of cancer and macular degeneration.The company was founded by Michael M. Strage and Robert Benezra on March 31, 1999 and is... 
More about the company
Latest news on ANGIOGENEX INC
05/14ANGIOGENEX : Management's Discussion and Analysis of Financial Condition and Res..
AQ
04/02ANGIOGENEX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RES..
AQ
2017ANGIOGENEX INC : Michael Aronstein to Head AngioGenex, Inc. Board of Directors
AC
2017ANGIOGENEX, INC. : Change in Directors or Principal Officers, Regulation FD Disc..
AQ
2017ANGIOGENEX : Management's Discussion and Analysis of Financial Condition and Res..
AQ
2008ANGIOGENEX INC COM USD0.001 : AngioGenex Reviews 2008 Achievements and Sets Goal..
PR
2008ANGIOGENEX INC COM USD0.001 : AngioGenex Appoints New CEO to Direct Development ..
PR
More news
Sector news : Biotechnology & Medical Research - NEC
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20Roche to Buy Rest of Cancer Firm -- WSJ
DJ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19Roche to Pay $2.4 Billion for Full Control of Foundation Medicine -- 2nd Upda..
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart ANGIOGENEX INC
Duration : Period :
Angiogenex Inc Technical Analysis Chart | AGGX | US03475U3014 | 4-Traders
Managers
NameTitle
Robert Benezra President, Chief Executive Officer & Director
Michael Charles Aronstein Non-Executive Chairman
Michael M. Strage Chief Operations Officer, Director & VP
Martin F. Murray Chief Financial Officer & Director
Sector and Competitors
1st jan.Capitalization (M$)
ANGIOGENEX INC-22.50%0
CELLTRION, INC.--.--%33 349
IQVIA HOLDINGS INC6.98%21 424
LONZA GROUP2.35%20 530
INCYTE CORPORATION-22.94%15 692
SEATTLE GENETICS, INC.22.95%10 577